Top Markets
Coin of the day
Easywell Biomedicals, Inc. Easywell Biomedicals, Inc.

Easywell Biomedicals, Inc.

1799
Rang in Aktien #20891
Easywell Biomedicals, Inc., together with its subsidiaries, develops,... Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; TLX-47, an anti-inflammatory drug; and TLX-024, an anticonvulsant. It also develops TWB-201 for Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company provides thermometers, medical devices, and health food and products. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Aktienkurs
$0.96033064
Zuletzt synchronisiert: 2026-08-21
Marktkapitalisierung
$119.74M
Veränderung (1 Tag)
0.67%
Veränderung (1 Jahr)
-33.99%
Land
TW
Handel Easywell Biomedicals, Inc. (1799)

Kategorie

P/B-Verhältnis für Easywell Biomedicals, Inc. (1799)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Easywell Biomedicals, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Easywell Biomedicals, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber